Anti-MRSA beta-lactams in development.
Ceftobiprole medocaril, the most advanced of the anti-MRSA (methicillin-resistant Staphylococcus aureus) beta-lactams in clinical development, has recently completed its first Phase III clinical trial, and has demonstrated non-inferiority to vancomycin. Phase II clinical trials have been initiated with PPI0903, which is, like ceftobiprole medocaril, an injectable pro-drug of a broad-spectrum cephalosporin with anti-MRSA activity, and with RO4908643, a carbapenem with more modest activity against MRSA.
Page
Malcolm G P
MG
Basilea Pharmaceutica Ltd., Grenzacherstrasse 487, CH-4005 Basel, Switzerland. malcolm.page@basilea.com
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D015195:Drug Design; D016106:Methicillin Resistance; D013211:Staphylococcus aureus / Q000187:drug effects*; D047090:beta-Lactams / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D047090:beta-Lactams